2023 was a successful year for drug discovery. According to Mullard et al. (2024), the FDA’s Center for Drug Evaluation and Research (CDER) approved 55 new drugs in 2023, marking a nearly 50% increase from the previous year. This growth has contributed to the expansion of the small molecule and biologic pharmacopoeia. The 10-year rolling average for new CDER approvals is now at 46 per year, the highest it has been in over 20 years. For more information and the full list of approvals, click here.
For further details on the findings, please refer to Mullard et al. (2024).
